Boston Scientific Corporation
PARIS, November 15, 2011 -
CRI's Amigo™ system allows remote control of Boston Scientific's leading cardiac ablation catheters
Boston Scientific Corporation (NYSE: BSX) is beginning to market the CRI Amigo™ system, a remote-controlled catheter system, and related accessories in select European countries through an exclusive agreement with Catheter Robotics, Inc.
PARIS, November 9, 2011 -
Now available for endoscopic dilation of the Sphincter of Oddi following sphincterotomy
Boston Scientific Corporation's (NYSE: BSX) CRE™ Wireguided Balloon Dilator is now CE marked for endoscopic dilation of the Sphincter of Oddi following sphincterotomy.
PARIS, September 27, 2011 -
- Five-year data from Research in Severe Asthma (RISA) Trial demonstrate maintenance ofstable lung function and absence of late clinical complications
- Patients in Europe with severe asthma can now benefit from uniqueand proven non-drug therapy
Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from the Research in Severe Asthma (RISA) Trial, demonstrating the long-term safety of bronchial thermoplasty (BT) in patients treated with the Company's Alair™ Bronchial Thermoplasty System.
LONDON, May 23, 2011 -
- New Technology Designed to Improve Lead Anchoring for Physicians to
be Introduced at INS World Congress
Boston Scientific Corporation (NYSE: BSX) today announced CE
Mark approval of the Clik(TM) Anchor for its Precision Plus(TM) Spinal Cord
Stimulator (SCS) System, the world's first rechargeable SCS device for
chronic pain management.
NATICK, Massachusetts and PARIS, May 23, 2011 -
- 12-Month Clinical Data Demonstrate Low Adverse Event Rates for Boston
Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) today announced
12-month results from its PLATINUM Small Vessel study, demonstrating
excellent safety and effectiveness outcomes for the 2.25 mm PROMUS
Element(TM) Everolimus-Eluting Platinum Chromium Stent System in treating
small vessel coronary disease.
More News
- Innovative Fine Needle Aspiration Technology Expands Diagnostic Capabilities in Pancreas and Gastrointestinal Tract
- World's Smallest and Thinnest High-Energy CRT-Ds and ICDs Offer new Features to Optimize Patient Management
- Reduction of Geographic Miss and Bail-out Stenting Observed With Highly Visible PROMUS Element Stent
- Third-Generation Bare-Metal Stent Implanted in the UK
- Third-generation bare-metal stent now available in CE Mark countries
- Boston Scientific Announces CE Mark Approval and First Implants for New Devices to Treat Heart Failure and Sudden Cardiac Death
- Boston Scientific Announces Australia and New Zealand Approval for its LATITUDE(R) Patient Management System
- Company's Fully Covered Metal Stent Now Approved for Use in Treating Benign Biliary Strictures
- Latest Innovation in Plastic Biliary Stent Technology Includes Features for Enhanced Deliverability, Efficiency and Procedural Control
- MADIT II Eight-Year Outcomes Analysis Shows That One Life is Saved for Every Eight Patients Who Receive an ICD
- Nine-month Results From PLATINUM Clinical Program Presented at TCT
- PROMUS(R) Element(TM) Stent Approved for Use in Diabetic and Heart Attack Patients in CE Mark Countries
- FDA Approval is Based on Results From the Company's Landmark MADIT-CRT Trial
- EVOLVE Trial to Evaluate Company's Fourth-Generation SYNERGY(TM) Drug-Eluting Coronary Stent
- Company Expands Market-leading Family of Neurovascular Stents
- Boston Scientific Announces First Patient Enrollment in MultiSENSE Clinical Trial
- MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
- Randomized Study of Nearly 3,000 Patients to Evaluate Company's Third-Generation Drug-Eluting Stent Technology
- Boston Scientific Announces Availability of New Connector System Designed to Simplify the Implant Procedure for Cardiac Devices
- Company's CRT-Ds Recommended for Asymptomatic and Mild Heart Failure Patients
- PERSEUS Trial Results Demonstrate Positive Safety and Efficacy Outcomes for Boston Scientific's Novel Platinum Chromium TAXUS(R) Element(TM) Stent System
- Value of the Service Recognized by Patients and Physicians
- Third-Generation Drug-Eluting Stents Now Available in Australia
- Boston Scientific Announces Enrollment of First Patient in Benign Stricture Study of WallFlex(R) Biliary RX Stent
- Boston Scientific Announces Completion of Enrollment in Aneurysm Coiling Clinical Trial
- Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets
